Posted by Michael Wonder on 18 Feb 2022
Agios announces FDA approval of Pyrukynd (mitapivat) as first disease-modifying therapy for haemolytic anaemia in adults with pyruvate kinase deficiency
17 February 2022 - Company to provide robust patient access programs, including $0 copays and free medication for eligible patients.
Agios Pharmaceuticals today announced that the U.S. FDA has approved Pyrukynd (mitapivat) in the U.S. for the treatment of haemolytic anaemia in adults with pyruvate kinase deficiency, a rare, debilitating, lifelong haemolytic anaemia.
